|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CWF19L2 |
Gene summary for CWF19L2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CWF19L2 | Gene ID | 143884 |
| Gene name | CWF19 like cell cycle control factor 2 | |
| Gene Alias | CWF19L2 | |
| Cytomap | 11q22.3 | |
| Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | Q2TBE0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 143884 | CWF19L2 | LZE4T | Human | Esophagus | ESCC | 5.12e-05 | 1.63e-01 | 0.0811 |
| 143884 | CWF19L2 | LZE20T | Human | Esophagus | ESCC | 8.74e-03 | 1.10e-01 | 0.0662 |
| 143884 | CWF19L2 | LZE24T | Human | Esophagus | ESCC | 1.21e-08 | 2.32e-01 | 0.0596 |
| 143884 | CWF19L2 | P4T-E | Human | Esophagus | ESCC | 6.17e-16 | 2.65e-01 | 0.1323 |
| 143884 | CWF19L2 | P5T-E | Human | Esophagus | ESCC | 9.97e-18 | 2.81e-01 | 0.1327 |
| 143884 | CWF19L2 | P8T-E | Human | Esophagus | ESCC | 1.37e-03 | 5.48e-02 | 0.0889 |
| 143884 | CWF19L2 | P9T-E | Human | Esophagus | ESCC | 9.52e-10 | 9.07e-02 | 0.1131 |
| 143884 | CWF19L2 | P10T-E | Human | Esophagus | ESCC | 5.76e-15 | 1.88e-01 | 0.116 |
| 143884 | CWF19L2 | P11T-E | Human | Esophagus | ESCC | 3.57e-06 | 2.37e-01 | 0.1426 |
| 143884 | CWF19L2 | P12T-E | Human | Esophagus | ESCC | 1.02e-18 | 2.69e-01 | 0.1122 |
| 143884 | CWF19L2 | P15T-E | Human | Esophagus | ESCC | 2.02e-08 | 3.64e-02 | 0.1149 |
| 143884 | CWF19L2 | P16T-E | Human | Esophagus | ESCC | 1.69e-07 | 1.38e-01 | 0.1153 |
| 143884 | CWF19L2 | P20T-E | Human | Esophagus | ESCC | 4.38e-08 | 8.57e-02 | 0.1124 |
| 143884 | CWF19L2 | P21T-E | Human | Esophagus | ESCC | 3.84e-13 | 2.12e-01 | 0.1617 |
| 143884 | CWF19L2 | P22T-E | Human | Esophagus | ESCC | 7.83e-08 | 2.97e-02 | 0.1236 |
| 143884 | CWF19L2 | P23T-E | Human | Esophagus | ESCC | 1.60e-08 | 1.44e-01 | 0.108 |
| 143884 | CWF19L2 | P24T-E | Human | Esophagus | ESCC | 4.22e-05 | 1.11e-02 | 0.1287 |
| 143884 | CWF19L2 | P26T-E | Human | Esophagus | ESCC | 1.47e-16 | 1.85e-01 | 0.1276 |
| 143884 | CWF19L2 | P27T-E | Human | Esophagus | ESCC | 6.94e-11 | 1.10e-01 | 0.1055 |
| 143884 | CWF19L2 | P30T-E | Human | Esophagus | ESCC | 2.79e-06 | 1.70e-01 | 0.137 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
| GO:0000375111 | Esophagus | ESCC | RNA splicing, via transesterification reactions | 248/8552 | 324/18723 | 3.05e-30 | 1.49e-27 | 248 |
| GO:0000377111 | Esophagus | ESCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:0000398111 | Esophagus | ESCC | mRNA splicing, via spliceosome | 244/8552 | 320/18723 | 2.52e-29 | 1.07e-26 | 244 |
| GO:00083807 | Liver | NAFLD | RNA splicing | 70/1882 | 434/18723 | 4.62e-05 | 1.10e-03 | 70 |
| GO:00003777 | Liver | NAFLD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1882 | 320/18723 | 6.21e-04 | 8.18e-03 | 51 |
| GO:00003987 | Liver | NAFLD | mRNA splicing, via spliceosome | 51/1882 | 320/18723 | 6.21e-04 | 8.18e-03 | 51 |
| GO:00003757 | Liver | NAFLD | RNA splicing, via transesterification reactions | 51/1882 | 324/18723 | 8.28e-04 | 1.02e-02 | 51 |
| GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
| GO:000037512 | Liver | Cirrhotic | RNA splicing, via transesterification reactions | 175/4634 | 324/18723 | 5.95e-30 | 7.47e-27 | 175 |
| GO:000037712 | Liver | Cirrhotic | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000039812 | Liver | Cirrhotic | mRNA splicing, via spliceosome | 172/4634 | 320/18723 | 4.02e-29 | 3.60e-26 | 172 |
| GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
| GO:000037522 | Liver | HCC | RNA splicing, via transesterification reactions | 228/7958 | 324/18723 | 1.47e-24 | 4.06e-22 | 228 |
| GO:000037722 | Liver | HCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000039822 | Liver | HCC | mRNA splicing, via spliceosome | 224/7958 | 320/18723 | 1.16e-23 | 2.62e-21 | 224 |
| GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
| GO:000037519 | Oral cavity | OSCC | RNA splicing, via transesterification reactions | 225/7305 | 324/18723 | 5.20e-29 | 2.99e-26 | 225 |
| GO:000037719 | Oral cavity | OSCC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| GO:000039819 | Oral cavity | OSCC | mRNA splicing, via spliceosome | 221/7305 | 320/18723 | 5.50e-28 | 2.18e-25 | 221 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CWF19L2 | SNV | Missense_Mutation | novel | c.1297N>G | p.Gln433Glu | p.Q433E | Q2TBE0 | protein_coding | tolerated(0.25) | benign(0.003) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CWF19L2 | SNV | Missense_Mutation | novel | c.1138N>G | p.His380Asp | p.H380D | Q2TBE0 | protein_coding | tolerated(0.16) | benign(0.009) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CWF19L2 | SNV | Missense_Mutation | novel | c.1052N>G | p.Ser351Cys | p.S351C | Q2TBE0 | protein_coding | tolerated(0.1) | possibly_damaging(0.511) | TCGA-A2-A3XZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CWF19L2 | SNV | Missense_Mutation | novel | c.17C>A | p.Ala6Glu | p.A6E | Q2TBE0 | protein_coding | deleterious(0.03) | benign(0.069) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CWF19L2 | SNV | Missense_Mutation | c.1474N>A | p.Glu492Lys | p.E492K | Q2TBE0 | protein_coding | deleterious(0) | probably_damaging(0.947) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CWF19L2 | SNV | Missense_Mutation | c.1033N>C | p.Glu345Gln | p.E345Q | Q2TBE0 | protein_coding | tolerated(0.15) | benign(0.011) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CWF19L2 | SNV | Missense_Mutation | c.2159G>C | p.Arg720Thr | p.R720T | Q2TBE0 | protein_coding | tolerated(0.9) | benign(0.003) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| CWF19L2 | SNV | Missense_Mutation | novel | c.1725G>T | p.Lys575Asn | p.K575N | Q2TBE0 | protein_coding | deleterious(0) | benign(0.196) | TCGA-OL-A6VR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CWF19L2 | insertion | Frame_Shift_Ins | novel | c.14_15insCCCTGTGCTGGAGGAATGGGATAAAG | p.Met5IlefsTer68 | p.M5Ifs*68 | Q2TBE0 | protein_coding | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CWF19L2 | insertion | Nonsense_Mutation | novel | c.953_954insA | p.Tyr318Ter | p.Y318* | Q2TBE0 | protein_coding | TCGA-AO-A12A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |